Companies /Healthcare

Adc Therapeutics SA

NYSE: ADCT Drug Manufacturers - Specialty & Generic
$1.32
▲ $0.00 (+0.00%) today
Markets closed · 7:29am ET
Today · % change

24/7 Wall St. View

Fundamentals

Market Cap
$168.5M
Profit Margin
-121.8%
Revenue (TTM)
$79.6M
EPS (TTM)
$-0.58
52-Week Range
$1 – $5
Street Target
$3.33

About ADC Therapeutics

ADC Therapeutics SA is a biotechnology firm focused on developing treatments for cancer. It specializes in creating antibody drug conjugates (ADCs) aimed at combating hematological malignancies and solid tumors. Its leading product, ZYNLONTA, is undergoing trials for specific lymphoma conditions. The company is also working on several other ADCs targeting various cancers, including a notable project in Hodgkin lymphoma and treatments for solid tumors and leukemia. Founded in 2011 and based in Switzerland, ADC Therapeutics collaborates with several global entities to advance its research and development efforts.

ADCT Coverage

3:29pm ET
Telecom & Wireless

ADC Telecom Goes To Confession (ADCT)

ADC Telecom (NASDAQ: ADCT) is trimming its fiscal revenue guidance and throwing out almost every other bit of key restructuring and financial data to offer some stability to the situation.  The telecom…

Douglas A. McIntyre